The World Market for Companion Diagnostic Tests

 
   Single User - $4,200
   Site License (one location, 10 users) - $6,300
   Corporate License - $8,400



Loading...
Published Jun 7, 2016 | 810 Pages | Pub ID: KLI15021881

The World Market for Companion Diagnostic Tests



The emergence of companion diagnostic tests, tests that identify which patients are expected to benefit from treatment with a specific therapy, has established a relatively new category of cancer test. Companion diagnostics increase the probability of clinical success by identifying patients with the presence of biomarkers or disease-specific therapeutic targets that can dramatically improve outcomes. Companion diagnostics provide insight into understanding disease processes and ways that medicines can work to counteract disease.  In Kalorama Information's report, The World Market for Companion Diagnostic Tests, we analyze the world market for companion diagnostic and personalized medicine diagnostics.

Market analysis in this report covers the world market for companion diagnostics, including:
  • World IVD Companion Diagnostics Test Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020
  • World IVD Companion Diagnostics Test Market by Disease Segment, 2015 (Cancer, Other)
  • Worldwide Companion Diagnostics Test Services Market, 2015 and 2020
The phrase “Companion Diagnostics Market” includes both the personalized medicine market and FDA-defined companion diagnostics. The personalized medicine market is a large and rapidly growing market, as researchers, pharmaceutical companies, and diagnostic companies are now starting to develop personalized medicine tests. Most of the market growth to date has been in oncology, but there remains considerable opportunity for this rapid growth in this and other areas. The report examines current and emerging applications of personalized medicine, including:
  • Selected Major Biomarkers in Oncology Personalized Medicine Tests
  • Selected Companies with Personalized Medicine Tests for Oncology
  • Selected Companies with Personalized Medicine Tests for Cardiovascular Disease/Disorders
  • Selected Companies with Personalized Medicine Tests for Neurological Disorders
  • Selected Companies with Personalized Medicine Tests for Autoimmune and Inflammatory Disorders; Other Immune Related Conditions
  • Selected Biomarkers and Other Tests for Antibiotic Resistance, and Companies Developing/Marketing these Biomarkers
  • Selected Companies with Other Personalized Medicine Infectious Disease Tests
  • Selected Companies with Personalized Medicine Tests for Therapeutic Drug Monitoring of Biological Drugs
  • Pharmacogenomic Biomarkers in Drug Labeling
  • Selected Companies with Personalized Medicine Tests for Drug Metabolism Genes
  • Selected Companies with Other Personalized Medicine Tests
Companies working in the field of personalized medicine need to understand both the pharmaceutical and diagnostic markets (including regulatory and other issues), but many companies do not have expertise in both fields. This has lead to many agreements and acquisitions, and a large number of diverse deals are discussed in this report, including:
  • Investments and Financings in Personalized Medicine/Companion Diagnostics
  • Selected Examples of Pharmaceutical Companies and Other Companies That Invested in Diagnostic Companies in Personalized Medicine
  • Mergers and Acquisitions in Personalized Medicine/Companion Diagnostics
  • Selected Examples of Pharmaceutical Companies That Acquired Diagnostic Companies or Have Diagnostic Divisions
  • Collaborations between Pharmaceutical and Diagnostic Companies
  • Selected Examples of Pharmaceutical That Entered into Agreements with Diagnostic Companies
  • Selected Other Pharmaceutical Company Agreements
  • Collaborations between Two Diagnostic Companies
  • Diagnostic Company Agreements with Clinical Laboratories
  • Diagnostic Company Agreements with Other Companies
  • Diagnostic Company Collaborations with Universities and Other Non-Profit Research Institutes (Including Government)
The growth in companion diagnostic testing is likely to continue, as many new therapies are being developed and commercialized. The emergence of these new therapies presents opportunities and also challenges for the diagnostics industry. Oncology is the largest segment of the personalized medicine market, and so market drivers for the cancer diagnostic market also drive the overall personalized medicine and companion diagnostics markets. The report discusses this and other market drivers and challenges in personalized medicine and companion diagnostics.



Companies in the Companion Diagnostics Market

The World Market for Companion Diagnostic Tests provides profiles of selected pharmaceutical companies that are active in the fields of companion diagnostics or personalized medicine. They include companies that market drugs that have associated companion diagnostic tests, pharmaceutical companies that are collaborating with diagnostic companies to develop companion diagnostic tests, and companies with their own internal capabilities and activities in companion diagnostics. These include:
  • AbbVie Inc.
  • Acumen Pharmaceuticals, Inc.
  • Adaptimmune Therapeutics plc
  • Amgen Inc.
  • ARCA biopharma, Inc.
  • ARIAD Pharmaceuticals, Inc.
  • Arno Therapeutics, Inc.
  • Array BioPharma Inc.
  • Astellas Pharma Inc.
  • AstraZeneca
  • Athera Biotechnologies AB
  • AVEO Oncology
  • Bayer AG
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Celldex Therapeutics, Inc.
  • Clovis Oncology, Inc.
  • Eli Lilly
  • Galena Biopharma, Inc.
  • GlaxoSmithKline plc
  • Idera Pharmaceuticals, Inc.
  • Janssen Pharmaceutical Companies of Johnson & Johnson
  • Merck & Co., Inc.
  • Merck KGaA (EMD Serono)
  • Novartis AG
  • Pfizer Inc.
  • Roche (F. Hoffmann-La Roche Ltd.) and Genentech (A Member of the Roche Group)
The World Market for Companion Diagnostic Tests also includes profiles of companies that are active in the discovery and/or commercialization of companion diagnostics or other in vitro diagnostic tests for personalized medicine. This includes diagnostic companies that market kits that are used by clinical laboratories, and also diagnostic companies that are commercializing their novel diagnostic tests as a service offered to physicians, with the tests performed in the company’s own CLIA certified laboratory. These include:
  • 20/20 GeneSystems, Inc.
  • A&G Pharmaceutical, Inc.
  • Abacus Diagnostica Oy
  • Abbott Laboratories
  • Accelerate Diagnostics, Inc.
  • Acobiom
  • ACT Genomics Co., Ltd.
  • Adaptive Biotechnologies Corporation
  • Admera Health (A GENEWIZ Company)
  • Advanced Cell Diagnostics
  • Aelan Cell Technologies
  • Affymetrix, Inc. (Acquired by Thermo Fisher Scientific)
  • Agena Bioscience Inc.
  • Agendia NV
  • Almac Group Limited
  • AltheaDx, Inc.
  • Amarantus BioScience Holdings, Inc.
  • Amoy Diagnostics Co., Ltd.
  • ANGLE plc
  • ARKRAY, Inc.
  • Assurex Health, Inc.
  • Asuragen, Inc.
  • Atlas Genetics Ltd
  • AutoGenomics, Inc.
  • Avant Diagnostics, Inc.
  • BacterioScan, Inc.
  • Beckman Coulter, Inc. (Subsidiary of Danaher Corporation)
  • Becton, Dickinson and Company (BD)
  • BG Medicine, Inc.
  • Biocartis
  • Biocept, Inc.
  • Biodesix, Inc.
  • BioFire Diagnostics, LLC. (Acquired by bioMérieux)
  • BioGenex
  • Biological Dynamics, Inc.
  • BioMarker Strategies
  • bioMérieux SA
  • BioMosaics Inc.
  • BioReference Laboratories, Inc. (BRLI) (Part of OPKO Health, Inc.)
  • bioTheranostics, Inc.
  • Biotype Diagnostic GmbH
  • Cancer Genetics, Inc.
  • Caprion, Inc.
  • CardioDx, Inc.
  • CardioGenics Holdings Inc.
  • CareDx, Inc.
  • Caris Life Sciences
  • Castle Biosciences, Inc.
  • Cepheid
  • Clarient Diagnostic Services, Inc. (A NeoGenomics Company)
  • CompanionDx
  • Crescendo Bioscience (A Myriad Company)
  • Cube Dx GmbH
  • Curetis AG
  • Cynvenio Biosystems, Inc.
  • Dako A/S (An Agilent Company)
  • Danaher Corporation
  • Definiens AG (Acquired by MedImmune, Part of AstraZeneca)
  • DiaCarta, Inc.
  • DiamiR, LLC
  • Diatech Pharmacogenetics srl
  • Diaxonhit
  • DNA Electronics Ltd. (DNAe)
  • EntroGen, Inc.
  • Enzo Biochem, Inc
  • Enzo Life Sciences, Inc.
  • Enzo Clinical Labs, Inc.
  • Epic Sciences, Inc.
  • Eutropics Pharmaceuticals
  • Exosome Diagnostics, Inc.
  • Foundation Medicine, Inc.
  • GeneCentric Diagnostics, Inc.
  • Genection, Inc. (An Invivoscribe Company)
  • Genelex Corporation
  • GeneNews Limited and Innovative Diagnostic Laboratory
  • Genomas, Inc.
  • GenomeDx Biosciences
  • Genomic Health, Inc.
  • Genomica S.A.U.
  • Genomind
  • Genoptix (A Novartis Company)
  • GenPath Oncology
  • Grifols, S.A.
  • Guardant Health, Inc.
  • HalioDx
  • Harmonyx Diagnostics
  • Helomics Corporation
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • Inform Genomics, Inc.
  • Inivata Ltd.
  • Insight Genetics, Inc.
  • InSilixa, Inc.
  • IntegraGen SA
  • Invivoscribe Technologies, Inc.
  • Iris BioTechnologies Inc.
  • Janssen Diagnostics/Janssen Diagnostics BVBA/Janssen Diagnostics, LLC/Janssen Diagnostics, LLC
  • Lab 21 (Part of the Novacyt Group of Companies)
  • Laboratory Corporation of America (LabCorp)
  • Leica Biosystems Inc. (A Danaher Company)
  • Luminex Corporation
  • Mayo Medical Laboratories and Mayo Clinic
  • Medical & Biological Laboratories Co., Ltd. (MBL)
  • MBL International Corporation
  • Metabolon, Inc.
  • Metamark Genetics, Inc.
  • MIODx
  • MolecularMD Corporation
  • Monogram Biosciences (LabCorp Specialty Testing Group)
  • Multiplicom NV
  • Myriad Genetics, Inc.
  • Myriad RBM, Inc.
  • NanoString Technologies, Inc.
  • NantOmics (Member of the NantWorks ecosystem of companies)
  • NeoGenomics, Inc./NeoGenomics Laboratories
  • NewGene Ltd.
  • New Oncology AG
  • NovellusDx
  • Nuclea Biotechnologies, Inc.
  • OncoDNA SA
  • Oncompass GmbH
  • OncoPlex Diagnostics (OncoPlexDx)(Part of NantOmics)
  • Oncospire Genomics
  • One Way Liver S.L. (OWL Metabolomics)
  • OPKO Health, Inc./OPKO Diagnostics
  • OvaGene Oncology Inc.
  • Oxford Cancer Biomarkers Ltd.
  • Oxford Gene Technology
  • Panagene Inc.
  • Personal Genome Diagnostics, Inc.
  • Protagen AG
  • QIAGEN N.V.
  • QuanDx Inc.
  • Quest Diagnostics
  • Qvella Corporation
  • RiboMed Biotechnologies, Inc.
  • Roche
  • Rosetta Genomics Ltd.
  • Siemens Healthcare Diagnostics
  • Siemens Clinical Laboratory
  • Symbiodx
  • Sysmex Corporation
  • Theranostics Health Inc. (Acquired by Avant Diagnostics, Inc.)
  • Thermo Fisher Scientific, Inc.
  • Transgenomic, Inc.
  • TrimGen Corporation
  • Trovagene, Inc.
  • Ventana Medical Systems, Inc. (Member of the Roche Group)
  • WOUNDCHEK Laboratories
The information presented in this report is derived from publicly available information sources such as company reports and announcements, government reports and databases, medical organization reports, medical associations, and other publications. The analysis is based on the author's industry knowledge combined with literature searches and discussions with industry professionals and experts in the areas of point-of-care tests, decentralized healthcare and healthcare economics.
In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times
We were unable to search inside this report.
No results matched your search criteria.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.